The purpose of this study is to treat participants with a diagnosis of depressive disorder to assess the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) and venlafaxine in the treatment of depressive disorders compared venlafaxine only (the optimal medication) and to rTMS only. fMRI will be performed to determine if treatment response is related to changes in fMRI, and use it to investigate the respondence to the treatments.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks
rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks
Yun chun Chen
Xi'an, Shaanxi, China
RECRUITINGThe primary outcome measure is remission
It will be evaluated using the Hamilton Depression Rating Scale (HDRS-17 \< 8)
Time frame: 1-6 weeks
fMRI
Time frame: 0,6 weeks
CGI
Using the Clinical Global Impression scale(CGI)
Time frame: 1-6 weeks
QIDS-C30
Time frame: 1-6 weeks
UKU Scale
Side effects will be assessed using the UKU Scale
Time frame: 1-6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.